{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:28:11Z","timestamp":1791444491136,"version":"4.3.3"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The study aimed to conduct a systematic review and meta-analysis comparing the efficacy of teprenone with control or other drugs for reducing the incidence of gastrointestinal (GI) adverse events in patients receiving long-term non-steroidal anti-inflammatory drugs (NSAIDs).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Databases of PubMed, Embase, BioMed Central, CENTRAL, and Google Scholar were searched up to November 10th, 2020 for randomized controlled trials (RCTs) comparing teprenone with control or other drugs. A random-effects model was used for the meta-analysis. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool was used for assessing the certainty of evidence.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Seven RCTs were included. Six compared teprenone with control and one with famotidine. Meta-analysis indicated a statistically significant reduced risk of GI ulcers in patients receiving teprenone as compared to control after 12 weeks\/3months (RR 0.37 95% CI 0.17, 0.18 <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 0% <jats:italic>p<\/jats:italic> = 0.01). Pooled data of three open-label studies indicated statistically significant reduction of GI symptoms in patients on teprenone as compared to control at 6 months and 12 months, but not at 3 months. Comparing teprenone with control, our analysis indicated non-significant but a tendency of better reduction in Modified Lanza Score (MLS) with teprenone. The RCT comparing teprenone to famotidine demonstrated better reduction of MLS with famotidine. The certainty of evidence-based on GRADE was deemed to be low.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Low-quality evidence indicates a beneficial role of teprenone in preventing GI injuries in patients receiving long-term NSAIDs. Further high-quality RCTs comparing teprenone with placebo as well as other gastroprotective drugs are needed to strengthen current evidence.<\/jats:p>","DOI":"10.3389\/fmed.2021.647494","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T04:34:16Z","timestamp":1617770056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of Teprenone for Prevention of NSAID-Induced Gastrointestinal Injury: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"8","author":[{"given":"Chongxiang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17430","article-title":"Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews","volume":"17","author":"Sutcliffe","year":"2013","journal-title":"Health Technol Assess (Rockv)."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar4174","article-title":"Use of NSAIDs in treating patients with arthritis","volume":"15","author":"Crofford","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cpcardiol.2017.01.006","article-title":"Upper gastrointestinal toxicity associated with long-term aspirin therapy: consequences and prevention","volume":"42","author":"Lavie","year":"2017","journal-title":"Curr Probl Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.amjmed.2011.01.018","article-title":"Effect of aspirin on mortality in the primary prevention of cardiovascular disease","volume":"124","author":"Raju","year":"2011","journal-title":"Am J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/j.1365-2036.2009.04086.x","article-title":"Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers","volume":"30","author":"Musumba","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01795.x","article-title":"Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs","volume":"18","author":"Sturkenboom","year":"2003","journal-title":"Aliment Pharmacol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1111\/j.1572-0241.2008.01995.x","article-title":"Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin","volume":"103","author":"Yeomans","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5056\/jnm18001","article-title":"Advantages and disadvantages of long-term proton pump inhibitor use","volume":"24","author":"Kinoshita","year":"2018","journal-title":"J Neurogastroenterol Motil."},{"key":"B9","doi-asserted-by":"publisher","first-page":"d2690","DOI":"10.1136\/bmj.d2690","article-title":"Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study","volume":"342","author":"Charlot","year":"2011","journal-title":"BMJ."},{"key":"B10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1177\/0018578719893378","article-title":"Cost-effective analysis of proton pump inhibitors in long-term management of gastroesophageal reflux disease: a narrative review","volume":"55","author":"Jamshed","year":"2020","journal-title":"Hosp Pharm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000106756","article-title":"Geranylgeranylacetone protects the human gastric mucosa from diclofenac-induced injury via induction of heat shock protein 70","volume":"75","author":"Yanaka","year":"2007","journal-title":"Digestion."},{"key":"B12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejphar.2010.11.020","article-title":"Protective effect of geranylgeranylacetone against loxoprofen sodium-induced small intestinal lesions in rats","volume":"652","author":"Iwai","year":"2011","journal-title":"Eur J Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0014-2999(98)00430-0","article-title":"Protective and preventive effects of teprenone on gastric mucosal lesions in rats","volume":"354","author":"Nishida","year":"1998","journal-title":"Eur J Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"B15","unstructured":"HigginsJ\n            ThomasJ\n            ChandlerJ\n            CumpstonM\n            LiT\n            PageM\n          CochraneCochrane Handbook for Systematic Reviews of Interventions. Version 62019"},{"key":"B16","first-page":"22024","article-title":"Study on protective mechanism of teprenone on aspirin-induced gastric mucosal injury","volume":"10","author":"Lu","year":"2013","journal-title":"Chinese J Postgrad Med."},{"key":"B17","first-page":"404","article-title":"Protection of gastric mucosa against aspirin-induced damage by teprenone","volume":"32","author":"Wu","year":"2012","journal-title":"Chinese J Dig."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/00365521.2019.1672781","article-title":"Teprenone for the prevention of low-dose aspirin-induced gastric mucosal injury in Helicobacter pylori-negative patients","volume":"54","author":"Chitapanarux","year":"2019","journal-title":"Scand J Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6532876","DOI":"10.1155\/2019\/6532876","article-title":"The protective effect of teprenone on aspirin-related gastric mucosal injuries","volume":"2019","author":"Zhao","year":"2019","journal-title":"Gastroenterol Res Pract."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/jgh.14614","article-title":"Teprenone improves gastric mucosal injury and dyspeptic symptoms in long-term nonsteroidal anti-inflammatory drug users","volume":"34","author":"Gong","year":"2019","journal-title":"J Gastroenterol Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jgh.12768","article-title":"Comparison of teprenone and famotidine against gastroduodenal mucosal damage in patients taking low-dose aspirin","volume":"29","author":"Takeuchi","year":"2014","journal-title":"J Gastroenterol Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.dld.2015.01.005","article-title":"Geranylgeranylacetone protects against small-intestinal injuries induced by diclofenac in patients with rheumatic diseases: a prospective randomized study","volume":"47","author":"Xiong","year":"2015","journal-title":"Dig Liver Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.3748\/wjg.v21.i25.7709","article-title":"Geographic differences in low-dose aspirin-associated gastroduodenal mucosal injury","volume":"21","author":"Iijima","year":"2015","journal-title":"World J Gastroenterol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s00535-013-0839-5","article-title":"Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study","volume":"49","author":"Uemura","year":"2014","journal-title":"J Gastroenterol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1365-2036.2005.02649.x","article-title":"Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin","volume":"22","author":"Yeomans","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"B26","first-page":"218","article-title":"Frequency of NSAID induced peptic ulcer disease","volume":"56","author":"Hamid","year":"2006","journal-title":"J Pak Med Assoc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.3748\/wjg.v18.i24.3167","article-title":"Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications","volume":"18","author":"Zhu","year":"2012","journal-title":"World J Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.3748\/wjg.v18.i18.2262","article-title":"Preventive effects of geranylgeranylacetone on rat ethanolinduced gastritis","volume":"18","author":"Ning","year":"2012","journal-title":"World J Gastroenterol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/0149-2918(95)80070-0","article-title":"Clinical evaluation of teprenone, a mucosal protective agent, in the treatment of patients with gastric ulcers: a nationwide, multicenter clinical study","volume":"17","author":"Shirakabe","year":"1995","journal-title":"Clin Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.gie.2013.12.030","article-title":"Irsogladine improves small-intestinal injuries in regular users of nonsteroidal anti-inflammatory drugs","volume":"80","author":"Isomura","year":"2014","journal-title":"Gastrointest Endosc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2165\/11633470-000000000-00000","article-title":"Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS Project)","volume":"35","author":"Castellsague","year":"2012","journal-title":"Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.phrs.2015.12.026","article-title":"Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: results of a pharmacovigilance reporting system","volume":"104","author":"Rafaniello","year":"2016","journal-title":"Pharmacol Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00535-009-0068-0","article-title":"The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy","volume":"44","author":"Shiotani","year":"2009","journal-title":"J Gastroenterol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1440-1746.2011.06949.x","article-title":"Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS)","volume":"27","author":"Hongo","year":"2012","journal-title":"J Gastroenterol Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-230X-12-42","article-title":"Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS)","author":"Sakurai","year":"2012","journal-title":"BMC Gastroenterol."},{"key":"B36","unstructured":""},{"key":"B37","unstructured":""}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.647494\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T04:34:21Z","timestamp":1617770061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.647494\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":37,"alternative-id":["10.3389\/fmed.2021.647494"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.647494","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"article-number":"647494"}}